Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00932893 · ClinicalTrials.gov registry record · Phase 3
An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 347
- Enrollment target
NCT00932893 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 347 participants.
The verdict
NCT00932893, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 347 participants
- Enrollment target
Study Summary
This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug.
Interventions
- DRUG Docetaxel
- DRUG Pemetrexed
- DRUG PF-02341066
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 347 participants |
| Start Date | 2009-09 |
| Est. Completion | 2016-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00932893
The ClinicalTrials.gov registry entry for NCT00932893 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 347 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT00932893 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00932893 about?
NCT00932893 is a clinical study titled "An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene". This is a Phase 3 trial comparing the safety and anti-tumor activity of PF-02341066 versus pemetrexed or docetaxel in patients with advanced non-small cell lung cancer with specific gene profile involving the ALK gene after failure of one previous chemotherapy regimen that included one platinum drug...
What is the current status of trial NCT00932893?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 347 participants. The study started on 2009-09. Estimated completion is 2016-01.
What interventions are being tested in trial NCT00932893?
The interventions under investigation include: Docetaxel (DRUG), Pemetrexed (DRUG), PF-02341066 (DRUG).
Who is sponsoring clinical trial NCT00932893?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.